Cellular Sciences   Report issue

For profit Phase 3
Founded: Elmsford NY United States (1997)
Status: No NME R&D (1997)

Organization Overview

First Clinical Trial
2004
NCT00262613
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Cellular Sciences, inc.

Active Ingredients

Drugs in Phase 3 Trials (2)

pyruvate (6 trials)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cystic Fibrosis (Phase 1)

Fibrosis (Phase 1)

Lung Diseases (Phase 2)

Lung Diseases, Obstructive (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 2